Drug
Nnc0491 6075
Nnc0491 6075: highest development phase Phase 1, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| NNC0491-6075 NCT05979428 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Nnc0491 6075 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.